Add to ORKGcontributed equally to first or last authorship Running title: PD-L1 blockade re-activates anti-CLL response Text word count: 4,050 Abstract word count: 196 Contact information for correspondence
Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revol...
Introduction: Escape from immunosurveillance is a hallmark of chronic lymphocytic leukemia (CLL) cel...
(A) Experimental outline for blocking B7/CD28 costimulation. Mice chronically infected with LCMV Cl-...
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of c...
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinase...
BACKGROUNDPD-1 and PD-L1 have been studied interchangeably in the clinic as checkpoints to reinvigor...
Contains fulltext : 200871.pdf (publisher's version ) (Closed access
Contains fulltext : 190712.pdf (publisher's version ) (Closed access)New immunothe...
International audienceThe co-inhibitory receptor programmed cell death (PD)-1, expressed by immune e...
PhDChronic lymphocytic leukaemia (CLL) is the most common adult leukaemia, and despite recent introd...
A better understanding of the biology of CLL has led to significant advances in therapeutic strategi...
(A) Experimental outline for evaluating whether LPS-activated DCs can improve the efficacy of PD-L1 ...
Contains fulltext : 109193.pdf (publisher's version ) (Open Access)Inhibitory mole...
Monoclonal antibodies that inhibit “immune checkpoint” through programmed cell death-1 and its ligan...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revol...
Introduction: Escape from immunosurveillance is a hallmark of chronic lymphocytic leukemia (CLL) cel...
(A) Experimental outline for blocking B7/CD28 costimulation. Mice chronically infected with LCMV Cl-...
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of c...
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinase...
BACKGROUNDPD-1 and PD-L1 have been studied interchangeably in the clinic as checkpoints to reinvigor...
Contains fulltext : 200871.pdf (publisher's version ) (Closed access
Contains fulltext : 190712.pdf (publisher's version ) (Closed access)New immunothe...
International audienceThe co-inhibitory receptor programmed cell death (PD)-1, expressed by immune e...
PhDChronic lymphocytic leukaemia (CLL) is the most common adult leukaemia, and despite recent introd...
A better understanding of the biology of CLL has led to significant advances in therapeutic strategi...
(A) Experimental outline for evaluating whether LPS-activated DCs can improve the efficacy of PD-L1 ...
Contains fulltext : 109193.pdf (publisher's version ) (Open Access)Inhibitory mole...
Monoclonal antibodies that inhibit “immune checkpoint” through programmed cell death-1 and its ligan...
which permits unrestricted use, distribution, and reproduction in any medium, provided the original ...
Immunotherapy with the programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade has revol...
Introduction: Escape from immunosurveillance is a hallmark of chronic lymphocytic leukemia (CLL) cel...
(A) Experimental outline for blocking B7/CD28 costimulation. Mice chronically infected with LCMV Cl-...